181 related articles for article (PubMed ID: 9280033)
1. Bayesian interim analysis of phase II cancer clinical trials.
Heitjan DF
Stat Med; 1997 Aug; 16(16):1791-802. PubMed ID: 9280033
[TBL] [Abstract][Full Text] [Related]
2. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Thall PF; Simon RM; Estey EH
J Clin Oncol; 1996 Jan; 14(1):296-303. PubMed ID: 8558211
[TBL] [Abstract][Full Text] [Related]
3. New designs for phase 2 clinical trials.
Estey EH; Thall PF
Blood; 2003 Jul; 102(2):442-8. PubMed ID: 12560224
[TBL] [Abstract][Full Text] [Related]
4. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
5. A predictive probability design for phase II cancer clinical trials.
Lee JJ; Liu DD
Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
[TBL] [Abstract][Full Text] [Related]
6. Implementing the EffTox dose-finding design in the Matchpoint trial.
Brock K; Billingham L; Copland M; Siddique S; Sirovica M; Yap C
BMC Med Res Methodol; 2017 Jul; 17(1):112. PubMed ID: 28728594
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
9. A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.
Li Y; Mick R; Heitjan DF
Clin Trials; 2012 Jun; 9(3):293-302. PubMed ID: 22523304
[TBL] [Abstract][Full Text] [Related]
10. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
Ryan EG; Brock K; Gates S; Slade D
BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
[TBL] [Abstract][Full Text] [Related]
11. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
12. Bayesian monitoring of phase II trials in cancer chemoprevention.
Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ
J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313
[TBL] [Abstract][Full Text] [Related]
13. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
15. Bayesian designs with frequentist and Bayesian error rate considerations.
Wang YG; Leung DH; Li M; Tan SB
Stat Methods Med Res; 2005 Oct; 14(5):445-56. PubMed ID: 16248347
[TBL] [Abstract][Full Text] [Related]
16. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Giles FJ; Kantarjian HM; Cortes JE; Garcia-Manero G; Verstovsek S; Faderl S; Thomas DA; Ferrajoli A; O'Brien S; Wathen JK; Xiao LC; Berry DA; Estey EH
J Clin Oncol; 2003 May; 21(9):1722-7. PubMed ID: 12721247
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials.
Thall PF; Simon R
Control Clin Trials; 1994 Dec; 15(6):463-81. PubMed ID: 7851108
[TBL] [Abstract][Full Text] [Related]
18. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
19. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Thall PF; Wathen JK; Bekele BN; Champlin RE; Baker LH; Benjamin RS
Stat Med; 2003 Mar; 22(5):763-80. PubMed ID: 12587104
[TBL] [Abstract][Full Text] [Related]
20. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]